Edition:
United Kingdom

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

10,050JPY
16 Nov 2018
Change (% chg)

¥62 (+0.62%)
Prev Close
¥9,988
Open
¥10,150
Day's High
¥10,250
Day's Low
¥10,015
Volume
553,200
Avg. Vol
1,336,174
52-wk High
¥11,490
52-wk Low
¥5,402

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.68
Market Cap(Mil.): ¥1,746,483.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.55

Financials

  4523.T Industry Sector
P/E (TTM): 57.32 31.23 33.59
EPS (TTM): 102.73 -- --
ROI: 4.05 15.57 15.05
ROE: 5.24 16.94 16.62

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

25 Oct 2018

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

25 Oct 2018

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

25 Oct 2018

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

25 Oct 2018

Nikkei rises to 2-week high on weak yen, pharmaceuticals

* Paper sector pushed up by brokerage's target price hike on co

24 Aug 2018

Nikkei rises as weak yen helps mood; Eisai soars

TOKYO, Aug 24 Japan's Nikkei rose on Friday as a weaker yen supported sentiment, with the pharmaceutical sector leading gains after a report that Eisai moved forward its mid-term profit goal by one year.

24 Aug 2018

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

17 Aug 2018

CORRECTED-(OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

* Wholesale price before discount is $16,970 for a 30-day supply

17 Aug 2018

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

16 Aug 2018

Eisai shares fall 18 pct after release of Alzheimer drug test details

TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

26 Jul 2018

Earnings vs. Estimates